Alzheimer’s and Memory Research
About Our Research
The Memory Disorders Program investigates new treatments designed to prevent and slow Alzheimer’s disease. Furthermore, we develop new tools to improve diagnostic and prognostic accuracy.
The Memory Disorders Program is actively recruiting subjects for clinical trials, volunteers are needed to participate in our research. Ongoing studies are those that are underway and are no longer recruiting new subjects.
If you are interested in joining a research study, please contact our program at memory@georgetown.edu.
Recruiting Studies
Ongoing Studies
- Longitudinal Early-onset Alzheimer’s Disease Study Protocol (LEADS)
- Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)
- A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer’s Disease (START STUDY)
- Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol (LiBBY)
- A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer’s Disease (Clarity AD)
- A Study of JNJ-63733657 in Participants With Early Alzheimer’s Disease (Autonomy)
- Metformin in Alzheimer’s Dementia Prevention (MAP)
- A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer’s Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (AHEAD 3-45 Study)
Joining Our Research
As the first step, we invite you to complete a pre-screening phone call. The call lasts about 20 minutes, and you will be asked about your family and medical history, willingness to participate in research procedures, contact information and demographics. This one time call helps us determine your eligibility for research.
If you are interested in joining a research study, please contact our program at memory@georgetown.edu.
Frequently Asked Questions
Please contact us if you have any specific questions.